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Summary The metallothionein content of ovarian tumours is considerably higher than that found in normal
ovaries (>100-fold differences in mean values, P <0.001). There was no difference between the metal-
lothionein content of tumours from patients who had completed chemotherapy, usually with a regimen
containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was
not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do
not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in
ovarian cancer.
The use of platinum containing drugs has increased the
response rates seen in patients with epithelial ovarian cancer.
Unfortunately these responses are followed by only a modest
increase in survival. This anomoly has been ascribed to the
development of resistance to these agents. This resistance is
manifested by a reduction in response rates upon relapse.
Several mechanisms of resistance have been suggested by in
vitro observations. These include alterations in drug trans-
port, glutathione, and glutathione S-transferase levels
(Teicher et al., 1987), levels and changes in DNA-Pt adduct
repair (Behrens et al., 1987), and elevated metallothionein
(Andrews et al., 1987). The contribution of these mechanisms
to clinical resistance is not known.
The metallothioneins are a range of low molecular weight
(6-7 kD) proteins involved in zinc homeostasis and heavy
metal detoxification (Karin & Richards, 1984). The proteins
are rich in sulphydryl groups and are therefore excellent
candidates for attacks by electrophiles (such as the platinum
drugs). Platinum has been shown to be bound to the metal-
lothionein fraction isolated from cells treated with cisplatin
(Endresen et al., 1984). Metallothionein levels have also been
associated with resistance to some alkylating agents, although
the proposed mechanism advances a role for these proteins as
cofactors or regulatory elements in the repair process, rather
than as direct chemical scavengers (Kaina et al., 1990).
There remains uncertainty as to whether data describing
mechanisms of resistance in vitro is relevant to human
tumours. This work describes the investigation of metal-
lothionein levels in tumour samples obtained either before
chemotherapy (initial debulking) or following combination
chemotherapy (second look laparotomy). The study was
designed to determine whether any gross change in metal-
lothionein levels occurred following chemotherapy. Metal-
lothionein levels were also measured in normal ovaries.
Materials and methods
Ovarian tumour specimens were provided by gynaecological
surgeons throughout the northwest region. One of the
authors (either A.M. or D.M.) attended the laparotomy to
supervise collection and storage of the samples.
Samples were collected at the time of operation,
immediately cut into approximately 3 x 3 mm blocks and
frozen in liquid nitrogen. Samples were then stored at
- 80°C until assayed. Tumour histology was reviewed by a
pathologist interested in gynaecological malignancies.
Similarly, samples of normal ovary were collected from
patients undergoing routine prophylactic oophorectomy at
the time of pelvic surgery for benign gynaecological disease.
The median age of the control group being 46 (39-54). Once
again histology was checked from the patient records and
adjacent sections to the test samples examined to confirm
normality.
Tumour samples were obtained at debulking laparotomy
or at second look surgery following chemotherapy. Of the 18
patients who had received chemotherapy 16 had received a
platinum containing drug. The chemotherapy regimens were:
carboplatin (300 mgm2) + cyclophosphamide (600 mgm2)
alternating with ifosfamide (5 gm2) + adriamycin
(50 mgm-2) at 4 week intervals for six cycles (n = 9); single
agent cisplatinum (100 mgm2) once every 4 weeks for six
cycles (n = 4); carboplatin (400 mgm-2) once every 4 weeks
for six cycles (n = 2); melphalan (1Omgday-' for 5 days,
over six cycles at 5 weeks intervals) (n = 2).
Measurement ofmetallothioneins
Metallothionein levels were determined as described by
Patierno et al. (1983). This method measures the binding of
203Hg to cell homogenates following trichloracetic acid treat-
ment. Metallothionein bound 203Hg was separated by spun-
column chromatography using Sephadex G-10 minicolumns.
This assay gives a measure of functional metallothionein
levels. All 203Hg was measured by gamma-counting (Packard
Minimax) and a standard curve constructed for each experi-
ment. All experiments were performed in triplicate and the
results expressed as the moles mercury bound per unit pro-
tein concentration. Experiments were repeated until errors of
less than 10% were achieved. The limits of detection were
less than 100 picomole of purified metallothionein. Appropri-
ate controls using purified metallothioneins and mercury
were carried out.
Cell extracts were prepared by homogenisation of tissue in
buffer (0.1 M potassium phosphate, pH 6.8, 4°C) using a
blender (Polytron 3000, 60s, max power), followed by
removal of particulate matter by centrifugation (MSE micro-
fuge, 2min). Metallothionein levels were measured immedi-
ately and no additional attempts to stop metallothionein
oxidation were made. The protein concentrations were deter-
mined using the Biorad protein assay system, according to
the manufacturer's instruction.
203Hg was obtained from New England Nuclear (Du Pont,
UK, HgCl2, 37-740 GBq gl).
Statistical analysis
This was carried out using the Minitab Analysis System
(Minitab Inc. State College, PA16801, USA) on a minicom-
puter (Microvax).
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Results
The metallothionein levels of tumours taken before and after
chemotherapy are shown in Table I. Corresponding levels
from normal ovaries were 0.0015, 0.005, 0.0510, 0.006,
0.003, 0.004, 0.005, 0.0057, 0.002, 0.038, 0.030 and 0.004
picomoles mercury bound per microgram protein. The median
levels for the three groups are 0.005 (normal ovary), 1.8
(ovarian tumour, no chemotherapy), and 4.05 (ovarian
tumour, previous chemotherapy) pmole Hg bound per pg
protein. Statistical analysis (Kruskal-Wallis) showed there to
be a significant difference between the three groups
(P <0.001). Further analysis (Mann-Whitney) showed that
this was entirely due to the difference between normal and
tumour tissue. There was no significant difference in metal-
lothionein content of tumours taken before and after
chemotherapy. [P(normal vs tumour (pre-chemotherapy))
<0.0001, P(normal vs tumour (post chemotherapy))
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= <0.0001, P(tumour (post) vs tumour (pre)) = 0.27].
Further analysis of these data showed that the metal-
lothionein levels were not related to:
(a) clinical reponse (Mann-Whitney, PR + static, (n = 8) vs
progressive disease (n = 9), P = 0.11)
(b) tumour size after initial laparotomy (Mann-Whitney,
P = 0.33)
(c) histology (Kruskal-Wallis, P = 0.28)
(d) differentiation state (Kruskal-Wallis, P = 0.55)
(e) disease stage (Kruskal-Wallis, P = 0.36)
(f) age (regression analysis, P = 0.70).
Discussion
The platinum drugs are amongst the most effective in the
treatment of ovarian malignancies. Their clinical usefulness is
limited by both toxicity and by the development of resistance
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Metallothionein content - expressed as picomoles Hg bound per microgram protein. Treatment - drugs used CY: cyclophosphamide, CB:
carboplatin, CIS: cisplatin, I: ifosfamide, A: adriamycin, M: melphelan. Residual disease at laparotomy - MRD: minimal residual disease,
Bulk: bulk tumour. Histology - M (mucinous) E (endometroid) S (serous) U (unclassified). Differentiation state - poor, medium, well.
Stage-Figo. Response to therapy - PR: partial response (>50% tumour reduction), Static: no change or <50% tumour reduction, Prog:
progressive disease. *Fallopian tube carcinoma. Samples 1-30 first look tumour pre-chemotherapy and 31-48 second look tumour
post-chemotherapy.
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(Zwelling, 1988). This study compares the metallothionein
content of ovarian tumours taken either before or after
cytotoxic chemotherapy. The chemotherapy regimens received
by the patients involved more than one agent in all but four
of the patients. The majority however received a platinum
drug (16/18). The response rate for these combinations has
previously been reported by our group at 70 + % (Gurney et
al., 1990). In spite of high initial response rate the majority
of patients relapse and die from their disease. Further
chemotherapy for patients relapsing after initial chemo-
therapy has been associated with poor results and the overall
response rate for such patients is 20% (Ozols, 1985). This
decrease is due to the development of clinical resistance
(Nash & Young, 1988).
Metallothioneins have been implicated in the mechanism of
resistance to platinum drugs in vitro (Andrews et al., 1987;
Bakka et al., 1981; Endresen et al., 1984), however the
evidence is confficting. Studies on cell lines have proposed
both causal (Kelley et al., 1988) and non-causal (Schilder et
al., 1990) relationships between metallothionein and resis-
tance to platinum drugs. Direct scavenging of platinum by
these proteins was not believed to be the major protective
effect in a cisplatinum resistant cell line as only a small
proportion (2%) of intracellular platinum was found to be
associated with metallothioneins (Andrews et al., 1987). A
cell line made resistant to heavy metals but cross resistant to
cisplatinum however showed elevated levels of metal-
lothioneins and bound significant amounts of platinum
(17%). This work also demonstrated that drug-resistant
ovarian cell lines selected by challenge with cisplatinum did
not show elevated metallothionein. Therefore whereas
elevated levels of metallothionein may protect against cis-
platinum, resistance developed against this agent does not
necessarily evoke this mechanism.
The data presented in this paper show that ovarian tumour
tissue has elevated levels of metallothioneins when compared
to normal ovary (> 100-fold increase in mean levels). This
increase is highly significant (P <0.001). A comparison of
tumours from patients who had and those who had not
received chemotherapy showed no statistically significant
difference in metallothionein levels. Similarly, although
numbers were relatively small, no difference was found
between patients who showed a response to chemotherapy
(n = 8) and those with progressive disease (n = 9). Further
analysis of these data showed no relationship between metal-
lothionein levels and age, stage, histology or tumour burden.
These data do not support a direct role for metallothion-
eins in resistance to platinum drugs in ovarian tumours in
vivo. An indirect role, such as that proposed in resistance to
nitrosoureas (Kaina et al., 1990) cannot, however, be ex-
cluded.
It is not known why tumours express such high levels of
metallothionein when compared to normal ovaries. The
tumour tissue is believed to arise from epithelial cells,
whereas the normal ovary contains many cell types (e.g.
including epithelium, germ cells and stromal cells etc.)
Therefore some of the observed differences may arise due to
cell type specific variations in metallothionein expression.
However for a difference of this size (100-fold) to occur the
tumour cells must either be expressing very high levels of
metallothionein or epithelial cells must express considerably
more than the other cell types found in normal ovaries.
The methodology used in this study cannot give any in-
formation on tumour heterogeneity, and the existence of
metallothionein-rich sub-populations within the tumour can-
not be excluded. The data show, however, that by the time of
laparotomy those tumours which have been exposed to
cytotoxic chemotherapy (generally with regimens containing
platinum) have similar metallothionein levels to tumours
taken before any chemotherapy has been given. These
tumours show reduced response rates (i.e. resistance) to fur-
ther therapy.
The metallothionein levels of tumours have been deter-
mined in two groups: tumours which have received no
chemotherapy and those which have undergone a course of
treatment. Unfortunately no information is available as to
the changes which may occur in metallothionein levels during
therapy. However no statistically significant difference is seen
in the metallothionein content of these two groups. However
a large decrease in clinical response is observed (70-20%). A
sequential study using tumours derived from the same patient
is at present ongoing.
It is not known whether the post-chemotherapy tumours
used in this work reflect the metallothionein status of any
residual surviving tumour cells, or whether the tumour has
arisen by reversion of the surviving tumour to a state similar
to that seen before chemotherapy. These questions would
again be best answered by the study of a disease in which
sequential biopsies can be taken during therapy.
In summary these data show that ovarian tumours have
elevated levels of metallothioneins compared to normal
ovarian tissue. No significant difference is seen in the metal-
lothionein levels of tumours taken before, or after, cytotoxic
chemotherapy. These data do not support a role for metal-
lothionein as a major determinant of response in ovarian
tumours in vivo. It is interesting to speculate on the role of
this overexpression of metallothionein in ovarian tumour
development. Experiments to elucidate the nature of this
overexpression are at present being carried out.
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